JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $202
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $202
摩根大通維持對爵士製藥的超額評級，將價格目標上調至202美元。
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $190 to $202.
JP Morgan分析師Jessica Fye維持對爵士製藥（納斯達克：JAZZ）的增持評級，並將目標股價從190美元提高至202美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。